Oesophageal adenocarcinoma

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
6 Unique sponsors
18 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 4
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Kinase inhibitor 3 substances
Antibody-drug conjugate (ADC) 3 substances
Antimetabolite 2 substances
Corticosteroid 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Platinum compound 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody 1 substance
Taxane 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Phase II: 2 Phase I/II: 2 Phase I: 2 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II

2 trials
  • Dr. Falk Pharma GmbH Commercial
    BUDESONIDE
    2023-507897-42-00 7 countries 2020 n=93
    Ended
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    CALCIUM FOLINATE PENTAHYDRATE; DOCETAXEL; DURVALUMAB; FLUOROURACIL; OXALIPLATIN
    2024-512980-29-00 1 country 2023 n=32
    Ended

Phase I/II

2 trials
  • Boehringer Ingelheim International GmbH Commercial
    CALCIUM FOLINATE; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE; ZANIDATAMAB; ZONGERTINIB
    2023-509566-38-00 5 countries 2024 n=181 Orphan
    Recruiting
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN; TUCATINIB
    2023-507555-29-00 4 countries 2024 n=68
    Recruiting

Phase I

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-509335-60-00 4 countries 2023 n=177
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-505858-18-00 4 countries 2024 n=175
    Halted

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 2 Phase I, Phase I/II 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
Dr. Falk Pharma GmbH Commercial 1 Phase II 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 0
Boehringer Ingelheim International GmbH Commercial 1 Phase I/II 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 1 Phase II 0
New trials by year
2020
1
2022
1
2023
2
2024
3
← All indication landscapes